MedTrace Logo

VerifyNow® PRUTest® Cardiovascular Population Expected Values On-Drug Study

NCT04492423 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2020-07-30

No results posted yet for this study

Summary

The purpose of this study is to determine the range of expected PRUTest values in patients in the intended use population receiving dual antiplatelet treatment with aspirin and prasugrel (Effient®), or ticagrelor (Brilinta®).

Conditions

  • Coronary Disease
  • Platelet Aggregation

Interventions

DIAGNOSTIC_TEST

VerifyNow PRUTest

VerifyNow PRUTest for platelet aggregation

Sponsors & Collaborators

  • Accriva Diagnostics

    lead INDUSTRY

Principal Investigators

  • Dominick J Angiolillo, M.D., Ph.D. · Uunversity of Florida Health Jacksonville

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-06
Primary Completion
2017-08-14
Completion
2018-03-22
FDA Device
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04492423 on ClinicalTrials.gov